Clinical Trials Logo

Inhalational Anthrax clinical trials

View clinical trials related to Inhalational Anthrax.

Filter by:
  • None
  • Page 1

NCT ID: NCT03569553 Not yet recruiting - Clinical trials for Inhalational Anthrax

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Start date: February 11, 2025
Phase:
Study type: Observational

This study will evaluate safety and clinical benefit of AIGIV used for treatment of patients with inhalational anthrax. This study will be implemented only in the event of a major anthrax exposure event. The study is designed to collect information on safety, clinical benefit (such as extent of anthrax illness and survival) and serum concentrations of AIGIV (for AIGIV pharmacokinetics) and anthrax toxins from inhalational anthrax patients treated with AIGIV.

NCT ID: NCT01952444 Completed - Clinical trials for Inhalational Anthrax

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Start date: October 29, 2013
Phase: Phase 1
Study type: Interventional

Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin

NCT ID: NCT01932437 Completed - Clinical trials for Inhalational Anthrax

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

Start date: July 26, 2013
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers

NCT ID: NCT01932242 Completed - Clinical trials for Inhalational Anthrax

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Start date: July 23, 2013
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and immunogenicity of repeat administration (two doses) of intravenous (IV) ETI-204.

NCT ID: NCT01929226 Completed - Clinical trials for Inhalational Anthrax

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

Start date: July 9, 2013
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.